Asahi Kasei in the news
Healthcare, homes, materials
Tamtam found 20 recent articles about Asahi Kasei.
- 食塩電解用電極に使用される貴金属のトレーサビリティ確保へ。旭化成・フルヤ金属・Circulariseが実証開始
Asahi Kasei, Furuya Metal, and Circularise are conducting a demonstration to track precious metals in chlor-alkali electrolysis electrodes, aiming for better recycling and supply chain transparency.
- 日本材料技研、環状カーボネートに関する旭化成株式会社との特許実施許諾契約を締結
Japan Material Technology has secured an exclusive license from Asahi Kasei for advanced cyclic carbonates and polycarbonate resins to enhance optical lens performance.
- Asahi Kasei: Closed-Loop Recycling for Iridium and Ruthenium
Asahi Kasei, Circularise, and Furuya Metal are establishing a closed-loop recycling system for iridium and ruthenium from chlor-alkali electrodes using digital traceability and Digital Product Passports.
- 旭化成、総合建設業の森組<1853>をTOBで完全子会社化
Asahi Kasei, through its subsidiary Asahi Kasei Homes, will fully acquire general construction company Morigumi via a tender offer to strengthen construction and expand real estate development.
- Asahi Kasei, Circularise and Furuya Metal launch precious metals traceability project
Asahi Kasei, Circularise, and Furuya Metal launched a project to improve traceability and recycling of precious metals in chlor-alkali electrolysis electrodes, leveraging digital technology to enhance supply chain transparency.
- Japan firms test precious-metal digital passports
Asahi Kasei and Furuya Metal are piloting digital passports with Circularise to track recycled precious metals in chlor-alkali electrolysis electrodes.
- 重要貴金属のDPP発行に向け、旭化成ら3社が実証を開始(MONOist)
Asahi Kasei, Circularise, and Furuya Metal started a demonstration to trace precious metals in salt electrolysis electrodes and issue Digital Product Passports.
- Asahi Kasei, Circularise, and Furuya Metal Launch Demonstration Project for Precious Metal Traceability in Chlor-Alkali Electrolysis Electrodes
Asahi Kasei, Circularise, and Furuya Metal are collaborating on a demonstration project to establish traceability for precious metals in chlor-alkali electrolysis electrodes using Digital Product Passports.
- 旭化成、Circulariseおよびフルヤ金属と食塩電解用電極の貴金属トレーサビリティ実証を開始
Asahi Kasei, Circularise, and Furuya Metal started a demonstration for precious metal traceability in salt electrolysis electrodes and Digital Product Passport issuance to boost resource circulation and supply chain transparency.
- 決算:旭化成9年ぶり最高益 27年3月期最終9%増、半導体材料が好調
Asahi Kasei expects a record net profit for the fiscal year ending March 2027, driven by strong sales of semiconductor materials for AI, leading to an increased dividend.
- Asahi Kasei Therapeutics Announces FDA Approval of HOVILPRI® (pritelivir) Tablets for Mucocutaneous HSV Lesions Refractory (With or Without Resistance) to Standard Antiviral Treatment in Immunocompromised Adults
Asahi Kasei Therapeutics received FDA approval for HOVILPRI (pritelivir) tablets to treat refractory mucocutaneous herpes simplex virus lesions in immunocompromised adults, offering a new oral treatment option with a novel mechanism of action.
- Aicuris acquisition delivers new drug for Asahi Kasei
Hovilpri, developed through Asahi Kasei's acquisition of Aicuris, received FDA approval for treating herpes simplex virus in immunocompromised adults, with an anticipated US launch by year-end.
- Asahi Kasei Acquisition Pays Off With FDA Approval for Novel Herpes Drug
Asahi Kasei's acquired drug, Hovilpri, received FDA approval for treating herpes simplex virus lesions in immunocompromised adults.
- US FDA nod validates Asahi Kasei's $920M Aicuris bet
Asahi Kasei's acquisition of Aicuris yielded Hovilpri, an FDA-approved treatment for herpes simplex virus in immunocompromised adults.
- FDA approves Asahi Kasei’s Hovilpri for refractory HSV
The FDA approved Asahi Kasei's Hovilpri for refractory HSV lesions in immunocompromised adults, offering a new oral treatment option with a novel mechanism of action.
- Asahi Kasei buyout yields novel FDA herpes nod in immunocompromised patients
Asahi Kasei's acquired drug, Hovilpri, secured FDA approval for treating refractory herpes simplex virus infections in immunocompromised adults, becoming a new treatment option.
- Mobility and Industrial Solutions Highlighted in Germany
Asahi Kasei showcased advanced polymer materials for automotive and industrial applications at Fakuma 2026, focusing on mobility electrification, interior design, and sustainable industrial systems.
- Asahi Kasei wins FDA approval for HOVILPRI in refractory HSV
Asahi Kasei received FDA approval for HOVILPRI (pritelivir), an oral treatment for refractory herpes simplex lesions in immunocompromised adults.
- US FDA approves Asahi Kasei’s drug for persistent herpes infections By Reuters
The FDA approved Asahi Kasei's drug, pritelivir, for treatment-resistant herpes in immunocompromised patients, with projected peak annual sales over $400 million.
- US FDA approves Asahi Kasei's drug for persistent herpes infections
Asahi Kasei's drug for persistent herpes infections has received approval from the US FDA.
Articles collected by Tamtam and kept when they are about the company, newest first. Each links to its source.
Selling to companies like Asahi Kasei?
Tamtam finds the companies that match your ideal customer, researches each account and tells you who to contact and when.
Find similar companies